Difference between revisions of "Team:Heidelberg/Achievements"

 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
{{Heidelberg/Header}}
 
{{Heidelberg/Header}}
 
{{Heidelberg/navbar}}
 
{{Heidelberg/navbar}}
−
 
+
<html>
−
Achievments
+
<head/>
−
 
+
<body>
−
 
+
<div class="container">
 +
<div class="content">
 +
<img src="https://static.igem.org/mediawiki/2015/b/b0/Heidelberg_media_banner_achievements.svg" style="width:100%; top:70px; margin-top: -10px; margin-left: -20px;">
 +
</div>
 +
</div>
 +
</body>
 +
</html>
 +
{{Heidelberg/pages/achievments}}
 
{{Heidelberg/Footer}}
 
{{Heidelberg/Footer}}

Latest revision as of 01:01, 19 September 2015

We established a NEW APPROACH to work with all types of functional nucleic acids, setting the foundations for their widespread use in synthetic biology

  • We developed a NEW STANDARD to easily clone functional RNAs for their expression in vitro and in vivo (RFC 110)

  • We established a NOVEL dual-color readout system to monitor the in vitro transcription of an RNA of interest based on a new ATP-switchable Spinach II aptamer

  • We established a NOVEL detection method for short ssDNAs and ssRNAs based on the HRP-mimicking DNAzyme

  • We designed de novo an ACTIVE SITE for twin ribozyme and proved its efficient cleavage activity in living yeast cells

  • We conceived and implemented an open-source SOFTWARE FOR THE DESIGN OF APTAMERS (MAWS) as a fast and affordable alternative to the laborious SELEX procedure

  • We conceived and implemented an open-source SOFTWARE ASSISTING THE DESIGN OF APTAZYMES (JAWS) to enable the construction of new sensing devices

  • We EXPERIMENTALLY VALIDATED several of our designed aptamers and aptazymes and fed the collected data back into the algorithms


We proved the PRINCIPLE that a ketamine-switchable aptazyme could be used to implement a TEST STRIPE to detect RAPE DRUGS in situ


We developed the APTABODY, an aptamer-based alternative to antibodies that drastically reduces the costs of performing WESTERN BLOTTING and allows to target proteins for which antibodies are not available